-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the context of constant changes in the pharmaceutical environment, personnel changes in the pharmaceutical industry are frequent and have even become the norm
.
In the first three quarters of 2021, large pharmaceutical companies, including Hengrui Pharmaceutical, Sinopharm, and Northeast Pharmaceutical, have experienced personnel changes
.
Since October, the industry resignation storm has intensified.
At least 19 senior executive positions in 18 domestic and foreign pharmaceutical companies, including Qianyuan Pharmaceutical, BeiGene, Lisheng Pharmaceutical, Stellite, AstraZeneca, and Novartis, have taken place within the month.
There is no shortage of positions such as general manager, president, vice president, and deputy general manager.
The reasons for resignation are still mainly due to work and personal reasons
.
Among them, in terms of domestic pharmaceutical companies, Qianyuan Pharmaceutical issued an announcement on the evening of October 22 that the company received a written resignation report from the company’s president, Mr.
Zhong Hairong, on October 22, 2021.
Mr.
Zhong Hairong applied for resignation from the company’s president due to work reasons
.
In addition, the company recently issued an announcement stating that the company's senior management has undergone personnel changes
.
Among them, Zhao Qun took the post of president, taking office on October 26, 2021
.
On October 22, the Human Resources Department of BeiGene announced to employees that the national leader of hematological tumor sales, Shi Hao, will leave the company on November 15, 2021 to seek external development opportunities
.
It is understood that the current successor has not yet been determined.
The blood tumor sales team will be managed by Liu Yan, the head of marketing of BeiGene Greater China for the time being.
The handover has already begun.
Starting from November 16, the blood team will directly Reported to Liu Yan
.
Berry Gene issued an announcement on the evening of October 7, stating that Mr.
Zhou Daixing applied to resign from the position of general manager of the company due to personal reasons and will continue to serve as a director in the company’s holding subsidiary Hong Kong Berry Genomics Co.
General manager
.
On October 11, Stellite issued an announcement stating that the board of directors had recently received a written resignation report from the company’s director and deputy general manager, Mr.
Li Huajun.
Mr.
Li Huajun applied to resign all of the above positions due to personal reasons.
After resignation, he will not hold any position in the company.
Position, resignation report will take effect on the day it is delivered to the board of directors
.
It is reported that as of the announcement date, Mr.
Li Huajun was granted 29,200 restricted shares in the company's 2020 restricted stock incentive plan
.
The restricted stocks he holds after his resignation will be implemented in accordance with the relevant regulations of the equity incentive system
.
Kangyuan Pharmaceutical also issued an executive change announcement in October stating that the company’s board of directors recently received a resignation report from Director, Deputy General Manager, Board Secretary and Chief Financial Officer Yin Honggang.
Yin Honggang applied to resign all of the above positions due to personal reasons.
After his resignation Will not hold any position in the company
.
In addition, the executives of foreign-funded pharmaceutical companies have also changed frequently
.
For example, on October 15th, Chen Pengquan, general manager of AstraZeneca China's digestion and respiratory nebulization business (GNR), announced to employees that He Yimin, assistant vice president of GNR, would resign
.
It is understood that He Yimin is the third executive who has resigned from AstraZeneca’s digestion and respiratory nebulization department since August this year, following Dong Lijun and Zhang Anwei; on October 22, Novartis Oncology’s AMACO regional market leader announced, Ji Bicheng will resign as the general manager of Novartis Oncology (China) and will be transferred to Novartis's AAA platform as the head of North America, effective from January 1, 2022
.
.
In the first three quarters of 2021, large pharmaceutical companies, including Hengrui Pharmaceutical, Sinopharm, and Northeast Pharmaceutical, have experienced personnel changes
.
Since October, the industry resignation storm has intensified.
At least 19 senior executive positions in 18 domestic and foreign pharmaceutical companies, including Qianyuan Pharmaceutical, BeiGene, Lisheng Pharmaceutical, Stellite, AstraZeneca, and Novartis, have taken place within the month.
There is no shortage of positions such as general manager, president, vice president, and deputy general manager.
The reasons for resignation are still mainly due to work and personal reasons
.
Among them, in terms of domestic pharmaceutical companies, Qianyuan Pharmaceutical issued an announcement on the evening of October 22 that the company received a written resignation report from the company’s president, Mr.
Zhong Hairong, on October 22, 2021.
Mr.
Zhong Hairong applied for resignation from the company’s president due to work reasons
.
In addition, the company recently issued an announcement stating that the company's senior management has undergone personnel changes
.
Among them, Zhao Qun took the post of president, taking office on October 26, 2021
.
On October 22, the Human Resources Department of BeiGene announced to employees that the national leader of hematological tumor sales, Shi Hao, will leave the company on November 15, 2021 to seek external development opportunities
.
It is understood that the current successor has not yet been determined.
The blood tumor sales team will be managed by Liu Yan, the head of marketing of BeiGene Greater China for the time being.
The handover has already begun.
Starting from November 16, the blood team will directly Reported to Liu Yan
.
Berry Gene issued an announcement on the evening of October 7, stating that Mr.
Zhou Daixing applied to resign from the position of general manager of the company due to personal reasons and will continue to serve as a director in the company’s holding subsidiary Hong Kong Berry Genomics Co.
General manager
.
On October 11, Stellite issued an announcement stating that the board of directors had recently received a written resignation report from the company’s director and deputy general manager, Mr.
Li Huajun.
Mr.
Li Huajun applied to resign all of the above positions due to personal reasons.
After resignation, he will not hold any position in the company.
Position, resignation report will take effect on the day it is delivered to the board of directors
.
It is reported that as of the announcement date, Mr.
Li Huajun was granted 29,200 restricted shares in the company's 2020 restricted stock incentive plan
.
The restricted stocks he holds after his resignation will be implemented in accordance with the relevant regulations of the equity incentive system
.
Kangyuan Pharmaceutical also issued an executive change announcement in October stating that the company’s board of directors recently received a resignation report from Director, Deputy General Manager, Board Secretary and Chief Financial Officer Yin Honggang.
Yin Honggang applied to resign all of the above positions due to personal reasons.
After his resignation Will not hold any position in the company
.
In addition, the executives of foreign-funded pharmaceutical companies have also changed frequently
.
For example, on October 15th, Chen Pengquan, general manager of AstraZeneca China's digestion and respiratory nebulization business (GNR), announced to employees that He Yimin, assistant vice president of GNR, would resign
.
It is understood that He Yimin is the third executive who has resigned from AstraZeneca’s digestion and respiratory nebulization department since August this year, following Dong Lijun and Zhang Anwei; on October 22, Novartis Oncology’s AMACO regional market leader announced, Ji Bicheng will resign as the general manager of Novartis Oncology (China) and will be transferred to Novartis's AAA platform as the head of North America, effective from January 1, 2022
.
